tbuckley/cabot-search huggingface dataset:
The retrospective analysis of single agent gemcitabine for biliary tract cancers
Authors: T. Kiba, S. Matsumoto, E. Hatano, A. Mori, S. Yasumi, R. Doi, T. Kitano, H. Ishiguro, K. Yanagihara, S. Teramukai, M. Fukushima
Journal: Journal of Clinical Oncology (2006)

14122 Background: At present, outcomes of advanced biliary tract cancers are dismal despite the prognosis of other many cancers are improving. Methods: We retrospectively analyzed survivals of 46 advanced biliary tract cancer patients, who were diagnosed between January 2001 and June 2005, and treated with gemcitabine 600–1,000 mg/m 2 as an intravenous 30-min infusion on days 1, 8, and 15 for every 28 days, thereafter. Results: The median age was 63 (range 41–76) with 28 males and 18 females. Twenty-nine (63.0%) had no prior chemotherapy and 18 (30.4%) patients were inoperable cases. One (2.2%) achieved complete response; 5 (10.9%) achieved partial responses; 25 (54.3%) had stable diseases; 9 (19.6%) had progressive disease; and 6 (13.0%) were not evaluated for response. The median survival time and the 1 year-survival of all advanced biliary cancer patients were 8.6 months and 43.9%, respectively, those of the patients, who had the recurrence or residual cancer lesions after surgical resection were 13.5 months and 68.8%, and those of the inoperable patients were 5.4 months and 8.3%. Patients reported grade 3/4 neutropenia/leucopenia (4.3%) and grade 3 thrombocytopenia (2.2%). Grade 3 non-hematologic toxicities were general fatigue (4.3%) and renal failure (2.2%). Multivariate analysis demonstrated that history of surgical resection with tumor recurrence or with residual tumor was the independent predictors for survival. Moreover, except the features of the history of surgical resection, the prognosis of patients with low levels of serum albumin (&lt; 3.7 g/dl) or ≥ 70 ages was worse than that of high levels of serum albumin (≥ 3.7 g/dl) or &lt; 70 ages. Conclusions: In the treatment of biliary tract cancer, it seems that surgical resection even with possible residual tumor is beneficial for patients with good surgical candidate. The present study also suggests the possibility that the prognosis of patients with low levels of serum albumin (&lt; 3.7 g/dl) or ≥ 70 ages might be worse than that of high levels of serum albumin (≥ 3.7 g/dl) or &lt; 70 ages. No significant financial relationships to disclose.
Individual Patient Data (IPD) Meta-Analysis of Rituximab Maintenance (MR) for Patients (pts) with Follicular Lymphoma (FL)
Authors: Liat Vidal, Anat Gafter-Gvili, Gilles Salles, Sami Bousseta, Bernice Oberman, Carmit Rubin, Marinus H.J. van Oers, Catherine Fortpied, Ruth Pettengell, Peter Dreger, Mathias Witzens-Harig, Umberto Vitolo, Andrea Evangelista, Maria Gomes da Silva, Hailun Li, Laurence Freedman, Thomas M Habermann, Ofer Shpilberg
Journal: Blood (2014)
TCT-699 Anatomic Deployment Index: A Novel Measure of SAPIEN 3 Transcatheter Heart Valve Performance
Authors: Rebecca Hahn, Maria Alu, Jonathon Leipsic, Pamela Douglas, Wael Jaber, Neil Weissman, Omar Khalique, Philipp Blanke, Rupa Parvataneni, Susheel Kodali, Vinod Thourani, Philippe Pibarot
Journal: Journal of the American College of Cardiology (2016)
MLL-AF4 and FLT3 Activation Synergize To Induce Multi Step Leukemogenesis.
Authors: Hiroki Yamaguchi, Koiti Inokuchi, Hideki Hanawa, Kazuhiro Sawaguchi, Yoshio Mitamura, Naoya Uchida, Mituharu Inami, Takashi Shimada, Kazuo Dan
Journal: Blood (2006)
TCT-69 A Randomized Comparison of The Second Generation Biodegradable Polymer Sirolimus-eluting Stent (EXCEL-II) and The First Generation EXCEL-I stent in Patients with De novo Coronary Lesions: Clinical and Angiographic Outcomes of the CREDIT II Trial
Authors: Yaling Han, Yuejin Yang, Bo Xu, Yong Sun, Zuyi Yuan, Haichang Wang, Jinghua Liu, Huiliang Liu, genshan ma, Geng Wang, Quanmin Jing, xiaozeng Wang
Journal: Journal of the American College of Cardiology (2016)
TCT-512 Fractional Flow Reserve-Guided Deferred Versus Complete Revascularisation in Patients With Diabetes Mellitus
Authors: Mark Kennedy, Rik Hermanides, Eliza Kaplan, Veemal Hemradj, Enrico Fabris, Petra Koopmans, Jan-Henk Dambrink, Marcel Gosselink, Arnoud van't Hof, Jan Paul Ottervanger, Vincent Roolvink, Wouter Remkes, Aize van der Sluis, Harry Suryapranata, Elvin Kedhi
Journal: Journal of the American College of Cardiology (2016)
A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma
Authors: Filemon S. Dela Cruz, Daniel Diolaiti, Andrew T. Turk, Allison R. Rainey, Alberto Ambesi-Impiombato, Stuart J. Andrews, Mahesh M. Mansukhani, Peter L. Nagy, Mariano J. Alvarez, Andrea Califano, Farhad Forouhar, Beata Modzelewski, Chelsey M. Mitchell, Darrell J. Yamashiro, Lianna J. Marks, Julia L. Glade Bender, Andrew L. Kung
Journal: Genome Medicine (2016)

Precision medicine approaches are ideally suited for rare tumors where comprehensive characterization may have diagnostic, prognostic, and therapeutic value. We describe the clinical case and molecular characterization of an adolescent with metastatic poorly differentiated carcinoma (PDC). Given the rarity and poor prognosis associated with PDC in children, we utilized genomic analysis and preclinical models to validate oncogenic drivers and identify molecular vulnerabilities. We utilized whole exome sequencing (WES) and transcriptome analysis to identify germline and somatic alterations in the patient's tumor. In silico and in vitro studies were used to determine the functional consequences of genomic alterations. Primary tumor was used to generate a patient-derived xenograft (PDX) model, which was used for in vivo assessment of predicted therapeutic options. WES revealed a novel germline frameshift variant (p.E1554fs) in APC, establishing a diagnosis of Gardner syndrome, along with a somatic nonsense (p.R790*) APC mutation in the tumor. Somatic mutations in TP53, MAX, BRAF, ROS1, and RPTOR were also identified and transcriptome and immunohistochemical analyses suggested hyperactivation of the Wnt/ß-catenin and AKT/mTOR pathways. In silico and biochemical assays demonstrated that the MAX p.R60Q and BRAF p.K483E mutations were activating mutations, whereas the ROS1 and RPTOR mutations were of lower utility for therapeutic targeting. Utilizing a patient-specific PDX model, we demonstrated in vivo activity of mTOR inhibition with temsirolimus and partial response to inhibition of MEK. This clinical case illustrates the depth of investigation necessary to fully characterize the functional significance of the breadth of alterations identified through genomic analysis.
TCT-265 One-year Outcome of Polymer-free Amphilimus-eluting Stent versus Biodegradable Polymer Biolimus-eluting Stent in Diabetes Mellitus Patients. Propensity-Matched Analysis of the ASTUTE (AmphilimuS iTalian mUlticenTre rEgistry) and INSPIRE-1 (Italian Nobori Stent ProspectIve REgistry-1) Registries.
Authors: Cosmo Godino, Carlo Andrea Pivato, Mauro Chiarito, michael donahue, Luca Testa, Dennis Zavalloni Parenti, David Rutigliano, luigi lucisano, Giacomo Maria Viani, Nicola Locuratolo, alberto monello, rosario parisi, riccardo colantonio, Damiano Regazzoli, Altin Palloshi, Diego Milazzo, Gianfranco Aprigliano, Annamaria Nicolino, Giuseppe Caramanno, Shahram Moshiri, rossella fattori, Gennaro Sardella, Alberto Cappelletti, Matteo Montorfano, Patrizia Presbitero, Francesco Bedogni, Carlo Briguori, Erica Manzan, Antonio Colombo
Journal: Journal of the American College of Cardiology (2016)
TCT-525 Initial experience with the use of fractional flow reserve in percutaneous intervention of transplant renal artery stenosis
Authors: Manuel Pereira Marques Gomes Junior, Claudia Alves, Adriano Barbosa, Jose Souza, Marco Tulio Souza, Cristiano Souza, Ricardo Peressoni Faraco, marcelo batista, José Osmar Pestana, Antonio Carlos Carvalho
Journal: Journal of the American College of Cardiology (2016)
Heterodimeric JAK-STAT Activation As a Mechanism of Persistence to JAK2 Inhibitor Therapy
Authors: Neha Bhagwat, Priya Koppikar, Outi Kilpivaara, Taghi Manshouri, Mazhar Adli, Ann Mullally, Omar Abdel-Wahab, Laura Leung, Abby Weinstein, Sachie Marubayashi, Aviva Goel, Mithat Gonen, Zeev Estrov, Benjamin L. Ebert, Gabriela Chiosis, Bradley Bernstein, Srdan Verstovsek, Ross L Levine
Journal: Blood (2011)
Nationwide Study of the Treatment of Mycotic Abdominal Aortic Aneurysms Comparing Open and Endovascular Repair
Authors: Karl Sörelius, Anders Wanhainen, Mia Furebring, Martin Björck, Peter Gillgren, Kevin Mani, David Lindström, Rebecka Hultgren, Carl-Magnus Wahlgren, Håkan Roos, Marcus Langenskiöld, Timothy Resch, Roberta Vaccarino, Linda Bilos, Artai Pirouzram, Conny Arnerlöv, Gabor Simo, Mats Svensson, Johan Magnusson, Håkan Astrand, Nils-Peter Gilgen, Stefan Mellander, David Korman, Khatereh Djavani-Gidlund, Markus Palm, Mårten Huss, Adam Bertszel, Michael Docter, Christer Drott, Andreas Öjersjö, Olle Nelzén, Tomas Wetterling, Ming Chu
Journal: Circulation (2016)

No reliable comparative data exist between open repair (OR) and endovascular aneurysm repair (EVAR) for mycotic abdominal aortic aneurysms (MAAAs). This nationwide study assessed outcomes after OR and EVAR for MAAA in a population-based cohort.All patients treated for MAAAs in Sweden between 1994 and 2014 were identified in the Swedish vascular registry. The primary aim was to assess survival after MAAA with OR and EVAR. Secondary aims were analyses of the rate of recurrent infections and reoperations, and time trends in surgical treatment. Survival was analyzed using Kaplan-Meier and log-rank tests. A propensity score-weighted correction for risk factor differences in the 2 groups was performed, including the operation year to account for differences in treatment and outcomes over time.We identified 132 patients (0.6% of all operated abdominal aortic aneurysms in Sweden). Mean age was 70 years (standard deviation, 9.2), and 50 presented with rupture. Survival at 3 months was 86% (95% confidence interval, 80%-92%), at 1 year 79% (72%-86%), and at 5 years 59% (50%-68%). The preferred operative technique shifted from OR to EVAR after 2001 (proportion EVAR 1994-2000 0%, 2001-2007 58%, 2008-2014 60%). Open repair was performed in 62 patients (47%): aortic resection and extra-anatomic bypass (n=7), in situ reconstruction (n=50), and patch plasty (n=3); 2 patients died intraoperatively. EVAR was performed in 70 patients (53%): standard EVAR (n=55), fenestrated/branched EVAR (n=8), and visceral deviation with stent grafting (n=7); no deaths occurred intraoperatively. Survival at 3 months was lower for OR than for EVAR (74% versus 96%, P<0.001), with a similar trend present at 1 year (73% versus 84%, P=0.054). A propensity score-weighted risk-adjusted analysis confirmed the early better survival associated with EVAR. During median follow-up of 36 and 41 months for OR and EVAR, respectively, there was no difference in long-term survival (5 years 60% versus 58%, P=0.771), infection-related complications (18% versus 24%, P=0.439), or reoperation (21% versus 24%, P=0.650).This study demonstrates a paradigm shift in treatment of MAAA in Sweden, with EVAR being the preferred treatment modality. EVAR was associated with improved short-term survival in comparison with OR, without higher associated incidence of serious infection-related complications or reoperations.
TCT-182 Impact of Gender and Age on Long-term Mortality in Acute Myocardial Infarction Patients with Anemia
Authors: Ae-Young Her, Seung-Woon Rha, Yong Hoon Kim, Byoung Geol Choi, Jae Kyeong Byun, Se Yeon Choi, Jun Hyuk Kang, Woo Hyeun Kim, Ja Yeon Choi, James Hall, Sung Hun Park, SunKi Lee, Hu Li, Jin Oh Na, Cheol Ung Choi, Jin Won Kim, Hong Euy Lim, Eung Ju Kim, Chang Gyu Park, Hong-Seog Seo, Dong Joo Oh
Journal: Journal of the American College of Cardiology (2016)
TCT-412 Long-term clinical outcomes after implantation of everolimus-eluting bioresorbable vascular scaffold in patients with acute myocardial infarction. 24-month clinical follow-up of the BVS STEMI First Study
Authors: Mariusz Tomaniak, Jiang Ming Fam, Cordula Felix, Robert-Jan van Geuns, Nicolas Van Mieghem, Evelyn Regar, Joost Daemen, Felix Zijlstra, Roberto Diletti
Journal: Journal of the American College of Cardiology (2016)
Outcome of Patients with Relapsed/Refractory (R/R) Acute Lymphoid Leukemia (ALL) after Failure of Inotuzumab Ozogamicin
Authors: Jad Chahoud, Hagop M. Kantarjian, Guillermo Garcia-Manero, Koji Sasaki, Tapan Kadia, Jorge E. Cortes, Maria R. Khouri, Farhad Ravandi, Jenny Dahl, Alessandra Ferrajoli, Jovitta Jacob, Naveen Pemmaraju, Naval Daver, Rebecca Garris, Elias Jabbour
Journal: Blood (2015)
TCT-13 Outcomes of chronic total occlusion percutaneous coronary intervention according to dissection/re-entry versus wire escalation techniques
Authors: Lorenzo Azzalini, Rustem Dautov, Soledad Ojeda, Barbara Bellini, Susanna Benincasa, Jorge Chavarria Viquez, Manuel Pan, Mauro Carlino, Antonio Colombo, Stéphane Rinfret
Journal: Journal of the American College of Cardiology (2016)
MINI01.01: Whole Body and Intracranial Efficacy of Ceritinib in ALK-inhibitor Naïve Patients with ALK+ NSCLC and Brain Metastases: Results of ASCEND 1 and 3
Authors: Alice T. Shaw, David R. Spigel, Daniel S.-W. Tan, Dong-Wan Kim, Ranee Mehra, Sergey Orlov, Keunchil Park, Chong-Jen Yu, Tony Mok, Makoto Nishio, Giorgio Scagliotti, Santosh Sutradhar, Dajana Cesic, Enriqueta Felip
Journal: Journal of Thoracic Oncology (2016)
TCT-89 Balloon pulmonary angioplasty for chronic thromboembolic hypertension: report of a two-year experience in a surgical center.
Authors: Philippe Brenot, Carlos Garcia Alonso, Benoit Gerardin, Ryad Bourkaib, Xavier Jais, Gerald Simonneau, Elie Fadel
Journal: Journal of the American College of Cardiology (2016)
RESECCIÓN ENDOSCÓPICA DE TUMORES SUBEPITELIALES. ESTUDIO RETROSPECTIVO MULTICÉNTRICO
Authors: G Vogel, F González-Huix, J Gornals, F Bas, R Ballester, A Vargas-García, C Loras, C Huertas, C Sánchez-Montes, G Fernández-Esparrach
Journal: Endoscopy (2016)

Introducción: Los tumores subepiteliales digestivos son un hallazgo habitual durante la realización de una endoscopia. La naturaleza de estos tumores es variada y no todos ellos tienen riesgo de degeneración por lo que no siempre es necesario un seguimiento o resección. El diagnóstico diferencial es difícil por la imagen y las biopsias endoscópicas son habitualmente negativas. En consecuencia, el manejo de estos tumores es muy variable y es habitual realizar un seguimiento endoscópico exhaustivo.
TCT-504 Comparison of Computed Tomography derived Fractional Flow Reserve to invasive Fractional Flow Reserve in Diagnosis of Functional Coronary Stenosis: A Meta-Analysis
Authors: Pradyumna Agasthi, Arun Kanmanthareddy, Obiora Egbuche, Vivek Yarlagadda, Susan Wilansky, F. David Fortuin, Rajesh Sachdeva
Journal: Journal of the American College of Cardiology (2016)
Excessive TNF-α Production Results from Reduction of c-Fos Via Aberrant Expression of Mir-34a in Neutrophils from Myelodysplastic Syndrome Patients
Authors: Yayoi Shikama, Meiwan Cao, Tomoyuki Ono, Michiko Anzai, Hideyoshi Noji, Xiaomin Feng, Hideo Kimura, Kazuei Ogawa, Kazuhiko Ikeda, Yasuchika Takeishi, Junko Kimura
Journal: Blood (2015)
Bim Is the Critical, and Bad and Bmf Are the Ancillary BH3-Only Proteins for Imatinib Mesylate-Induced Apoptosis of Bcr/Abl-Positive Leukemias.
Authors: Junya Kuroda, Hamsa Puthalakath, Philippe Bouillet, Mark S. Cragg, Priscilla N. Kelly, Andrew W. Roberts, Shinya Kimura, Oliver G. Ottmann, Andreas Strasser
Journal: Blood (2005)
TCT-243 Second generation drug-eluting stents or coronary bypass surgery in patients with three-vessel coronary disease
Authors: Reo Hata, Kazushige Kadota, Yusuke Hyodo, Suguru Otsuru, Seiji Habara, Hiroyuki Tanaka, Yasushi Fuku, Tsuyoshi Goto
Journal: Journal of the American College of Cardiology (2016)
Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical Trials
Authors: Catherine M. Tangen, Phyllis J. Goodman, Cathee Till, Jeannette M. Schenk, M. Scott Lucia, Ian M. Thompson
Journal: Journal of Clinical Oncology (2016)

Purpose To identify factors related to who undergoes a prostate biopsy in a screened population and to estimate the impact of biopsy verification on risk factor–prostate cancer associations. Patients and Methods Men who were screened regularly from the placebo arms of two large prostate cancer prevention trials (Prostate Cancer Prevention Trial [PCPT] and Selenium and Vitamin E Cancer Prevention Trial [SELECT]) were examined to define incident prostate cancer cohorts. Because PCPT had an end-of-study biopsy, prostate cancer cases were categorized by a preceding prostate-specific antigen/digital rectal examination prompt (yes/no) and noncases by biopsy-proven negative status (yes v no). We estimated the association of risk factors (age, ethnicity, family history, body mass index, medication use) with prostate cancer and quantified differences in risk associations across cohorts. Results Men 60 to 69 years of age, those with benign prostatic hyperplasia, and those with a family history of prostate cancer were more likely, and those with a higher body mass index (≥ 25), diabetes, or a smoking history were less likely, to undergo biopsy, adjusting for age and longitudinal prostate-specific antigen and digital rectal examination. Medication use, education, and marital status also influenced who underwent biopsy. Some risk factor estimates for prostate cancer varied substantially across cohorts. Black ( v other ethnicities) had odds ratios (ORs) that varied from 1.20 for SELECT (community screening standards, epidemiologic-like cohort) to 1.83 for PCPT (end-of-study biopsy supplemented with imputed end points). Statin use in SELECT provided an OR of 0.65 and statin use in in PCPT provided an OR of 0.99, a relative difference of 34%. Conclusion Among screened men enrolled in prostate cancer prevention trials, differences in risk factor estimates for prostate cancer likely underestimate the magnitude of bias found in other cohorts with varying screening and biopsy recommendations and acceptance. Risk factors for prostate cancer derived from epidemiologic studies not only may be erroneous but may lead to misdirected research efforts.
Validation of Digital-PCR Analysis through Programmed imatinib Interruption in Q-RT-PCR Negative Chronic Myeloid Leukemia Patients
Authors: Silvia Mori, Elisabetta Vagge, Philipp le Coutre, Elisabetta Abruzzese, Bruno Martino, Ester Pungolino, Chiara Elena, Ivana Pierri, Sarit Assouline, Anna D'Emilio, Antonella Gozzini, Pilar Giraldo, Fabio Stagno, Arnon Nagler, Alessandra Iurlo, Christian Rizzo, Alessia Fossati, Enrico Maria Pogliani, Dong-Wook Kim, Alessandra Pirola, Rocco Piazza, Carlo Gambacorti-Passerini
Journal: Blood (2013)
TCT-569 Validation of Novel Combined IVUS/OCT Catheter using Ex-Vivo Samples: Qualitative Examination of Human Cadaver Specimens
Authors: Jonathan Toma, Brian Li, Natasha Alves-Kotzev, Mark Harduar, Jill Weyers, Anna Zavodni, Jagdish Butany, Brian Courtney
Journal: Journal of the American College of Cardiology (2016)
TCT-346 Impact of anemia after coronary stenting on long-term outcomes of patients with coronary disease
Authors: Lin Jiang, Jinqing Yuan, Runlin Gao, Bo Xu, Chen He, Ying Song, Yi Yao, Changdong Guan, Ping Jiang, Yuejin Yang, Ru Liu, Na Xu, Lihua Xie, Xiao-Fang Tang, Jing-jing Xu, Jia-Hui Zhang, Yuan-liang Ma, Huan-Huan Wang
Journal: Journal of the American College of Cardiology (2016)
ANÁLISIS PROSPECTIVO DE LA SEGURIDAD DE LA SEDACIÓN CON PROPOFOL EN MONOTERAPIA POR ENFERMERÍA SUPERVISADA POR EL ENDOSCOPISTA EN PACIENTES SOMETIDOS A ULTRASONOGRAFÍA ENDOSCÓPICA (USE)
Authors: C Huertas Nadal, M Figa Francesch, H Uchima Hoecklin, M Hombrados Verde, D Busquets Casals, X Aldeguer Mantè
Journal: Endoscopy (2016)

En comparación con la endoscopia estándar, la ultrasonografía endoscópica (USE) es un procedimiento más largo y complejo que requiere mayores dosis de sedantes. Constan pocos estudios que evalúen la seguridad de la sedación supervisada por el endoscopista.
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome
Authors: Gautam Borthakur, Zeev Estrov, Guillermo Garcia-Manero, Betsy Williams, Jay K. Wathen, Marina Konopleva, Jan Burger, Alessandra Ferrajoli, Solly George, Hagop Kantarjian
Journal: Blood (2008)
Phase IIb Randomized Study of CPX-351 Vs. Conventional Cytarabine + Daunorubicin in Newly Diagnosed AML Patients Aged 60-75: Safety Report.
Authors: Jeffrey E Lancet, Eric J. Feldman, Jonathan E. Kolitz, Martin S. Tallman, Donna E. Hogge, Rami S. Komrokji, Michael T. Chiarella, Arthur C. Louie
Journal: Blood (2009)
P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment
Authors: Roy S. Herbst, Paul Baas, Jose L. Perez-Gracia, Enriqueta Felip, Dong-Wan Kim, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn, Margarita Majem, Mary Jo Fidler, Veerle Surmont, Gilberto De Castro, Marcelo Garrido, Yue Shentu, Marisa Dolled-Filhart, Ellie Im, Edward B. Garon
Journal: Journal of Thoracic Oncology (2016)
High CD34+ Cell Dose Is a Significant Factor for Hematologic Reconstitution of Patients with Multiple Myeloma (MM) or AL-Amyloidosis Undergoing Autologous Peripheral Blood Stem Cell Transplantation.
Authors: Jens Klaus, Doris Herrmann, Ute Hegenbart, Gerlinde Egerer, Friedrich W. Cremer, Iris Breitkreutz, Axel Benner, Stefan Fruehauf, Thomas Moehler, Anthony D. Ho, Hartmut Goldschmidt
Journal: Blood (2004)
TCT-475 Effect of Stent Diameter in Women Undergoing Percutaneous Coronary Intervention with Early- and New-Generation Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration
Authors: Gennaro Giustino, Camilla Melegari, Usman Baber, Samantha Sartori, Gregg Stone, Martin Leon, Takeshi Kimura, Melissa Aquino, Serdar Farhan, George Dangas, Giulio Stefanini, Stephan Windecker, Philippe Gabriel Steg, Raban Jeger, Marco Valgimigli, Adnan Kastrati, Alaide Chieffo, Roxana Mehran
Journal: Journal of the American College of Cardiology (2016)
TCT-164 Pressure-Controlled Intermittent Coronary Sinus Occlusion Reduces Infarct Size and Results in Functional Recovery After STEMI; Interim analysis of an ongoing trial
Authors: Mohaned Egred, Alan Bagnall, Ioakim Spyridopoulos, Ian Purcell, Rajiv Das, Nick Palmer, Ever Grech, Ajay Jain, Gregg Stone, Robin Nijveldt, Roger Kessels, Azfar Zaman
Journal: Journal of the American College of Cardiology (2016)